BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2019 2:14:06 AM | Browse: 796 | Download: 1153
 |
Received |
|
2019-07-30 08:52 |
|
Peer-Review Started |
|
2019-07-30 08:52 |
|
To Make the First Decision |
|
2019-08-19 00:33 |
|
Return for Revision |
|
2019-08-23 09:58 |
|
Revised |
|
2019-09-05 13:14 |
|
Second Decision |
|
2019-09-06 12:25 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2019-09-09 05:56 |
|
Articles in Press |
|
2019-09-09 05:56 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2019-09-19 02:44 |
|
Typeset the Manuscript |
|
2019-09-27 11:14 |
|
Publish the Manuscript Online |
|
2019-09-30 02:14 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected byan in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Basic Study |
| Article Title |
Oncogenic ADAM28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Li Wei, Jing-Yun Wen, Jie Chen, Xiao-Kun Ma, Dong-Hao Wu, Zhan-Hong Chen and Jiang-Long Huang |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Jiang-Long Huang, MD, Associate Professor, Chief Doctor, Department of Gastrointestinal Surgery, The Third Affiliated Hospital of Sun Yat-sen University, No.600 Tianhe Rd, Guangzhou 510630, Guangdong Province, China. leichende21743@163.com |
| Key Words |
ADAM28; Drug resistance; Overexpression; Poor prognosis; Drug metabolism; Gemcitabine |
| Core Tip |
This study demonstrated that ADAM28 was overexpressed in pancreatic cancer, and the ADAM28 level was elevated in the gemcitabine-resistant pancreatic cancer cells. Furthermore, ADAM28 overexpression could predict the poor prognosis in pancreatic cancer. Also, overexpression of ADAM28 could attenuate the cell viability inhibition by gemcitabine. Similarly, knockdown of ADAM28 could enhance the cell viability inhibition by gemcitabine. Interestingly, ADAM28 was identified as a mediator, which was closely involved in the regulation of the drug resistance signaling pathway. ADAM28 was identified as a novel therapeutic target for pancreatic cancer, especially in the drug resistance of gemcitabine. |
| Publish Date |
2019-09-30 02:14 |
| Citation |
Wei L, Wen JY, Chen J, Ma XK, Wu DH, Chen ZH, Huang JL. Oncogenic ADAM28 induces gemcitabine resistance and predicts poor prognosis in pancreatic cancer. World J Gastroenterol 2019; 25(37): 5590-5603 |
| URL |
https://www.wjgnet.com/1007-9327/full/v25/i37/5590.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v25.i37.5590 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
